886361-97-3 Usage
Uses
Used in Pharmaceutical Industry:
IMIDAZO[1,2-A]PYRIDINE-6-CARBOHYDRAZIDE is used as a building block for the synthesis of pharmaceutical compounds. Its unique structure allows it to be a key component in the development of new drugs with potential therapeutic applications.
Used in Medicinal Chemistry Research:
IMIDAZO[1,2-A]PYRIDINE-6-CARBOHYDRAZIDE is utilized in medicinal chemistry research for studying its potential biological activities. IMIDAZO[1,2-A]PYRIDINE-6-CARBOHYDRAZIDE has shown promise in anti-cancer and antimicrobial properties, making it a valuable candidate for further investigation and development.
Used in Organic Synthesis:
IMIDAZO[1,2-A]PYRIDINE-6-CARBOHYDRAZIDE is used as a useful intermediate in organic synthesis. It plays a crucial role in the preparation of diverse functional materials, contributing to the advancement of the chemical industry and the creation of innovative products.
Check Digit Verification of cas no
The CAS Registry Mumber 886361-97-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,8,6,3,6 and 1 respectively; the second part has 2 digits, 9 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 886361-97:
(8*8)+(7*8)+(6*6)+(5*3)+(4*6)+(3*1)+(2*9)+(1*7)=223
223 % 10 = 3
So 886361-97-3 is a valid CAS Registry Number.
886361-97-3Relevant academic research and scientific papers
Design, synthesis and structure-activity relationships of 1,3,4-oxadiazole derivatives as novel inhibitors of glycogen synthase kinase-3β
Saitoh, Morihisa,Kunitomo, Jun,Kimura, Eiji,Hayase, Yoji,Kobayashi, Hiromi,Uchiyama, Noriko,Kawamoto, Tomohiro,Tanaka, Toshimasa,Mol, Clifford D.,Dougan, Douglas R.,Textor, Garret S.,Snell, Gyorgy P.,Itoh, Fumio
experimental part, p. 2017 - 2029 (2009/05/26)
Glycogen synthase kinase-3β (GSK-3β) is implicated in abnormal hyperphosphorylation of tau protein and its inhibitors are expected to be a promising therapeutic agents for the treatment of Alzheimer's disease. Here we report design, synthesis and structure-activity relationships of a novel series of oxadiazole derivatives as GSK-3β inhibitors. Among these inhibitors, compound 20x showed highly selective and potent GSK-3β inhibitory activity in vitro and its binding mode was determined by obtaining the X-ray co-crystal structure of 20x and GSK-3β.
